Brief: Eledon Reports Data From Ongoing Phase 1b Trial Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At World Congress Of Nephrology
31/03/2023 11:07
March 31 (Reuters) - Eledon Pharmaceuticals Inc
ELDN.O :
* ELEDON REPORTS DATA FROM ONGOING PHASE 1B TRIAL EVALUATING
TEGOPRUBART IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION AT
WORLD CONGRESS OF NEPHROLOGY
* ELEDON REPORTS DATA FROM ONGOING PHASE 1B TRIAL EVALUATING
TEGOPRUBART IN PATIENTS UNDERGOING KIDNEY TRANSPLANTATION AT
WORLD CONGRESS OF NEPHROLOGY
* ELEDON PHARMACEUTICALS INC - RESULTS FROM THREE
PARTICIPANTS
DEMONSTRATED NO INCIDENCE OF ACUTE REJECTION AT DURATIONS OF 56,
154, AND 232 DAYS
* ELEDON PHARMACEUTICALS INC - STRONG GRAFT FUNCTION
OBSERVED IN
ALL THREE PARTICIPANTS WITH MEAN EGFRS ABOVE 70 ML/MIN/1.73M2 AT
MEASURED TIMEPOINTS
* ELEDON PHARMACEUTICALS INC - DATA FROM 16 PARTICIPANTS IN
PHASE
2 IGAN STUDY DEMONSTRATED TEGOPRUBART TO BE SAFE AND WELL
TOLERATED,
* ELEDON PHARMACEUTICALS INC - DATA FROM 16 PARTICIPANTS IN
PHASE
2 IGAN STUDY WAS REPORTED WITH NO SERIOUS OR SEVERE ADVERSE
EVENTS
Source text for Eikon: ID:nGNX13kc81
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial